Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz purchased 20,000 shares of Compass Therapeutics stock in a transaction on Tuesday, January 31st. The stock was bought at an average price of $4.05 per share, for a total transaction of $81,000.00. Following the completion of the acquisition, the chief executive officer now owns 5,471,873 shares in the company, valued at approximately $22,161,085.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Compass Therapeutics Trading Down 0.2 %

CMPX stock opened at $3.99 on Thursday. Compass Therapeutics, Inc. has a 12 month low of $1.25 and a 12 month high of $5.65. The company has a 50-day moving average price of $4.64 and a 200 day moving average price of $3.63. The stock has a market cap of $503.50 million, a PE ratio of -9.50 and a beta of 1.36.

Compass Therapeutics (NASDAQ:CMPX – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). Sell-side analysts forecast that Compass Therapeutics, Inc. will post -0.39 EPS for the current year.

Analyst Ratings Changes

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in Compass Therapeutics in the 3rd quarter valued at about $33,000. Bank of New York Mellon Corp purchased a new stake in Compass Therapeutics in the 3rd quarter valued at about $55,000. Marshall Wace LLP boosted its position in Compass Therapeutics by 118.4% in the 3rd quarter. Marshall Wace LLP now owns 51,816 shares of the company's stock valued at $117,000 after buying an additional 28,089 shares during the period. Renaissance Technologies LLC boosted its position in Compass Therapeutics by 397.5% in the 2nd quarter. Renaissance Technologies LLC now owns 66,165 shares of the company's stock valued at $175,000 after buying an additional 52,865 shares during the period. Finally, Silverarc Capital Management LLC purchased a new stake in Compass Therapeutics in the 3rd quarter valued at about $598,000. 54.27% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.

See Also

• Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
• Bed Bath & Beyond Is Circling the Drain
• Allegro Microsystems Is A Well-Positioned Semiconductor Stock
• Scotts Miracle-Gro Hits Bottom, Reversal In Play
• Altria is a Great Recession Stock, Long-Term Outlook Uncertain
• Novavax Shares Jumped in January While Others Slipped

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.